Senseonics Eversense E3 Ascensia Diabetes Care
The Eversense E3 system. [Image from Ascensia/Senseonics]

Senseonics (NYSE:SENS) shares ticked up after hours today on fourth-quarter results that beat the consensus forecast.

Shares of SENS rose 1.7% at 96¢ apiece after the market closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day up 1.7%.

The Germantown, Maryland-based long-term implantable CGM maker posted profits of $11.6 million in the quarter. That amounts to 2¢ per share on sales of $5.6 million for the three months ended Dec. 31, 2022.

Senseonics posted an 86.9% bottom-line slide on sales growth of 40%. Its EPS topped Wall Street estimates of breakeven, while revenues beat projections of $4 million.

Get the full story at our sister site, Drug Delivery Business News.